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The effects of blood group types on the risk of COVID-19 infection and its clinical outcome
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Background/aim: COVID-19 (Coronavirus disease of 2019) is an infectious disease outbreak later on declared as a pandemic, caused
by the SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). It spreads very rapidly and can result in severe acute respiratory
failure. The clinical studies have shown that advanced age and chronic diseases increase the risk of infection. However, influence of the
blood groups on COVID-19 infection and its outcome remains to be confirmed. The aim of this study is to investigate whether there
exists a relationship between the blood groups of the patients and risk of SARS-CoV-2 infection and the clinical outcomes in COVID-19
patients.
Material and method: 186 patients with PCR confirmed diagnosis of COVID-19 were included in this study. Age, sex, blood groups,
comorbidities, need for intubation and intensive care unit follow up and mortalities of the patients were analyzed retrospectively. 1881
healthy individuals, who presented to the Hacettepe University Blood Bank served as the controls.
Results: The most frequently detected blood group was blood group A (57%) amongst the COVID-19 patients. This was followed by
blood group O (24.8%). The blood group types did not affect the clinical outcomes. The blood group A was statistically significantly
more frequent among those infected with COVID-19 compared to controls (57% vs. 38%, P < 0.001; OR: 2.1). On the other hand, the
frequency of blood group O was significantly lower in the COVID-19 patients, compared to the control group (24.8% vs. 37.2%, P: 0.001;
OR: 1.8).
Conclusions: The results of the present study suggest that while the blood group A might have a role in increased susceptibility to the
COVID-19 infection, the blood group O might be somewhat protective. However, once infected, blood group type does not seem to
influence clinical outcome.
Key words: Blood groups, COVID-19, SARS-COV-2, susceptibility, clinical outcome

1. Introduction
COVID-19 was first described as a serious infection leading
to significant morbidity and mortality in Wuhan, China
in January 2020 [1]. World Health Organization (WHO)
declared COVID-19 infection caused by SARS-CoV-2 virus as
a pandemic on March 2020. SARS-COV-2 is beta coronavirus
that is closely related to SARS-CoV, both viruses use the
angiotensin-converting enzyme-related carboxypeptidase
(ACE2) in order to enter the cell [1,2]. COVID-19 disease
has been observed over 5,5 million people worldwide as of
May 25, 2020; and it has caused the death over 350,000 of
these patients. Many studies have shown that advanced
age, male sex, and comorbidities of the person increase the
risk and severity of the infection [2]. To date, there is no
specific biological marker that has been demonstrated to

predict the disease. Many previous studies indicated that
the connection between hepatitis B and the Norwalk virus
infection with the blood groups [3,4]. Few studies on SARSCoV-1 demonstrated that there exists a relationship between
infection risk and the blood types and that the blood group
O was somewhat protective against the SARS-CoV-1 [5,6].
There are only few clinical studies examining the
relationship between SARS-CoV-2 and the blood groups. In
these studies, it was demonstrated that the blood group O had
a negative predictive effect and the blood group A was more
frequent in patients who presented with severe pulmonary
damage [7–9]. The aim of this study is to investigate the
distribution and relationship between the blood groups
amongst the COVID-19 patients and their clinical outcomes
at a referral university hospital.
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2. Materials and methods
2.1. Patient population
The present study included 207 patients who were followed
at Hacettepe University School of Medicine Hospitals
between 10/03/2020 and 05/05/2020 with the COVID-19
infection who were positive for the SARS-CoV-2 RNA
test through PCR from the nasopharyngeal swab, and
who were approached in accordance with the treatment
guidelines of the Turkish Ministry of Health. The medical
records of patients were retrospectively analysed. The
patients, whose blood group analysis that were not done
at our hospital, were later on contacted, and their blood
groups were also obtained. A total of 186 patients were
evaluable for the final statistical analysis. The remaining
21 patients were excluded from the study because their
blood group information was not reliable or the patients
could not be reached. Clinical data including age, sex,
comorbidies, intubation needs, intensive care admissions
and outcome of the patients were obtained from medical
records.
Due to the existing protocols of the hospitals of
Hacettepe University Faculty of Medicine, all of the
ethical considerations were strictly followed. As a standard
care/action of the hospitals of the Hacettepe University
Faculty of Medicine, it has been recognized from the
patient records that all of the studied patients gave
informed consent at the time of admission to the hospital
for diagnostic/therapeutic procedures as standards of
care. Local Ethical Committee approval was obtained
from Hacettepe University numbered GO 20/434 and
additionally, Turkish Health Ministry approval was also
obtained on May 4th, 2020 for this study as required.

As for the comorbidities, histories of cardiovascular
disease, respiratory disease, obesity, diabetes mellitus, and
malignancy were screened. Hypertension, coronary artery
disease, congestive heart failure, and arrhythmias were
classified as cardiovascular diseases; COPD and asthma were
classified as respiratory diseases. Clinical outcomes were
determined as the need for intubation, the need for ICU, and
death.
In order to determine the normal distribution of the
blood groups, 1881 healthy individuals, who applied to the
Hacettepe University Blood Bank affiliated with our center
between 01/03/2020 and 01/05/2020, were included as the
control group. The blood group distributions, age and sex of
these patients were recorded.
2.2. Statistical analysis
Analyses were made using SPSS version 25.0 (IBM Corp.,
Armonk, NY, USA). The distribution between the blood
groups of the patient and control groups was evaluated using
chi-square and Fisher Exact tests. The impacts of blood groups
and comorbidities on the clinical outcomes were evaluated
using logistic regression analysis. Hosmer-Lemeshow test
was used for goodness-of-fit. The cases with the P-value
below 0.05 were accepted as statistically significant.
3. Results
The clinical characteristics and outcomes of 186 patients
included in the study according to their blood groups are
presented in Tables 1 and 2. The median age of patients
was 42 (19–92) and the percentage of female patients was
46.2%. The most frequently detected blood group was blood
group A with 57% amongst the COVID-19 patients. This was
followed by blood group O with 24.8%. There was a history

Table 1. The distribution of the blood groups according to the clinical characteristics (CVD: Cardiovascular disease, DM: Diabetes
mellitus, RD: Respiratory disease; m: male; f: female).
n

(m/f)
(N/%)

P

Age
(median)

P

CVD (N)
P
(n/%)

Obesity
P
(n/%)

DM
(n/%)

P

RD
(n/%)

P

Malignancy
P
(n/%)

0.99

7 (6.6)
7 (3.8)

0.39

A
Non-A

106 58/48 (54.7/45.3)
43 (19–84)
0.76
80 42/38 (52.5/47.5)
41 (20–92)

0.83

20 (18.9)
15 (18.8)

0.98

6 (5.7)
3 (3.8)

0.54

12 (11.3)
8 (7.5)
0.12
4 (5)
6 (7.5)

B
Non-B

20 9/11 (45/55)
0.4
166 91/75 (54.8/45.2)

0.46

4 (20)
31 (18.7)

0.88

2 (10)
7 (4.2)

0.25

0
16 (9.6)

0.14

2 (10)
1 (5)
0.65
12 (7.2)
9 (5.4)

0.93

AB
14 8/6 (57.1/42.9)
33.5 (20–64)
0.79
Non-AB 172 92/80 (53.5/46.5)
42.5 (19–92)

0.17

0
35 (20.3)

0.06

0
9 (5.2)

0.38

1 (7.1)
15 (8.7)

0.84

0
1 (7.1)
0.26
14 (8.1)
9 (5.2)

0.76

O
Non-O

46 25/21 (54.3/45.7)
41 (23–84)
0.92
140 75/65 (53.6/46.2)
43 (19–92)

0.58

11 (23.9)
24 (17.1)

0.30

1 (2.2)
8 (5.7)

0.33

3 (6.5)
13 (9.3)

0.56

4 (8.7)
1 (2.2)
0.72
10 (7.1)
9 (6.4)

0.26

Rh–
Rh+

26 15/11 (57.7/42.3)
47 (20–73)
0.66
160 85/75 (53.1/46.9)
41.5 (19–92)

0.44

3 (11.5)
32 (20)

0.30

2 (7.7)
7 (4.4)

0.46

0
16 (10)

0.09

1 (3.8)
4 (15.4)
0.44
13 (8.1)
6 (3.8)

0.015

Total

186

680

100/86
(53.8/46.2)

48 (26–92)
42 (19–84)

42 (19–92)

35

9

16

14

10
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of cardiovascular disease in 35 patients, obesity in 9 patients,
diabetes mellitus in 16 patients, respiratory disease in 14
patients, and malignancy in 10 patients. Of the 10 patients
with a history of malignancy, 3 had colon adenocarcinoma,
2 had non-Hodgkin lymphoma, 2 had MDS-RAEB2, 1 had
HCC, 1 had bladder adenocarcinoma and 1 had pancreatic
adenocarcinoma.
The distribution of the patient and control groups
according to their blood groups is presented in Table 3. When
the healthy control group was compared to the COVID-19
patient group, it was observed that the COVID-19 infection
rate was statistically significantly higher in those with
blood group A (57% vs. 38%, P <0.001; OR: 2.1). Though,
COVID-19 was significantly more seen with the blood group
A, on the other hand, Rh factor did not make any significant
difference (P > 0.05)
It was observed that the blood group O was significantly
lower in the COVID-19 patient group in comparison to the
controls (24.8% vs. 37.2%, P: 0.001; OR: 1.8). There was no
difference between blood groups of B and AB.

The effect of blood groups on clinical outcomes of
COVID-19 patients are presented in Table 4. No significant
effect of ABO and Rh systems were demonstrated on the
clinical outcomes.
4. Discussion
A total of 186 COVID-19 patients, who were followed at
the Hacettepe University, were included in the present
study. It was observed that blood group A was more
frequent and the blood group O was less frequent in
COVID-19 patients compared to the control group. The
blood group A was significantly more frequent and the
blood group O was less frequent amongst the COVID-19
patients when compared to the controls (P < 0.001 and P:
0.001, respectively)
When we looked at the effect of blood groups and Rh
type on the clinical outcomes, it was demonstrated that the
blood groups did not have significant predictive effects on
the need for intubation, need for ICU hospitalization and
mortality; and that the most significant factors affecting the

Table 2. The distribution of the blood groups according to the outcomes of COVID-19 (ICU: Intensive
care unit).
n

ICU
( n/%)

P

Intubation
( n/%)

P

ex
( n/%)

A
Non-A

106
80

17 (16)
16 (17.7)

0.76

7 (6.6)
4 (5.1)

0.66

6 (5.7)
3 (3.8)

0.54

B
Non-B

20
166

3 (15.8)
28 (16.9)

0.4

0
11 (6.6)

0.24

2(10)
7 (4.2)

0.25

AB
Non-AB

14
172

4 (28.6)
27 (15.8)

0.21

1 (7.1)
10 (5.8)

0.84

0
9 (5.2)

0.38

O
Non-O

46
140

7 (15.2)
24 (17.3)

0.74

3 (6.5)
8 (5.8)

0.84

1 (2.2)
8 (5.7)

0.33

Rh–
Rh+

26
160

6 (23.1)
25 (15.7)

0.35

2 (7.7)
9 (5.7)

0.68

1 (3.8)
8 (5)

0.79

Total

186

31

11

P

9

Table 3. The comparison of ABO blood groups in patient and control groups (The reference for
each group is all other 3 groups for ABO blood groups) (OR: Odds ratio).
Patient (n/%)

Control (n/%)

OR

P

95% CI

A

106 (57)

716 (38)

2.1 (1.5–2.9)

<0.001

1.84–1.89

B

20 (10.8)

277(14.7)

1.4 (0.8–2.3)

0.155

1.90–1.96

AB

14 (7.5)

188 (10)

1.3 (0.7–2.3)

0.364

1.89–1.96

O

46 (24.8)

701 (37.2)

1.8 (1.2–2.5)

0.001

1.92–1.95

Rh–

26 (14)

174 (9.2)

ref

Rh+

160 (86)

1708 (90.8)

1.2 (0.9–1.4)

ref
0.321

1.86–1.91

681
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Table 4. The effects of blood groups on clinical outcomes of COVID-19.
intubation

ICU

P

OR

P

OR

P

OR

A vs. non-A

0.66

1.32 (0.37–4)

0.94

1.03 (0.39–2.7)

0.35

2.73 (0.31–23.4)

B vs. non-B

0.99

-

0.96

1.03 (0.23–4.5)

0.19

5.01 (0.42–58.8)

AB vs. non-AB

0.84

1.23 (0.1–10.4)

0.32

2 (0.4–8.5)

0.99

-

O vs. non-O

0.66

1.14 (0.2–4.5)

0.74

1.16 (0.4–2.9)

0.35

2.72 (0.33–22.4)

Rh+ vs. Rh–

0.68

1.38 (0.28–6.8)

0.44

1.49 (0.53–4.1)

0.84

1.23 (0.14–10.5)

clinical outcomes were age and the history of comorbidity.
Few studies evaluated were evaluated in blood groups in
terms of the needs for intubation, ICU hospitalization and
clinical outcomes [7,8].
There have been studies indicating the predictive
effect of ABO blood groups on the Helicobacter pylori,
Norwalk virus, and SARS-CoV [6]. In a previous study,
conducted with 42 healthcare professionals in Hong Kong
during the SARS epidemic period, it was presented that
those with blood group O had a lower incidence of SARSCoV infection than the non-O (OR, 0.18; 95% confidence
interval, 0.04–0.81). The patients with blood group B also
demonstrated a tendency to the disease; however, there
was no statistical significance (OR: 1.46) [5]. In an animal
model, which was carried out to present the mechanism of
this result, it was found that the anti-A antibodies found in
individuals with blood group O inhibited the interaction of
SARS-CoV-1 virus S spike protein and the ACE-2 receptor
[10].
A number of studies have been carried out on this
subject since the beginning of the SARS-CoV-2 pandemic.
First of all, in a study on 265 COVID-19 patients, it was
presented that the blood group O was less frequent in severe
COVID -19 patients who required long hospitalization
(P < 0.01), and the blood group A was more frequent in
patients with severe COVID-19 infections compared to
the normal population (0.017) [10]. Two different studies
have also demonstrated the possible protective effect of the
blood group O [7,9,].
The relationship between ABO blood groups and
cardiovascular diseases was well established previously
[11]. It is known that thrombotic risks decrease significantly
in blood group O compared to the non-O [11, 12]. Studies

mortality

have shown that the micro thrombosis developing in the
COVID-19 infection in pulmonary vascular bed lead to
a serious contribution in the acute respiratory syndrome;
therefore, the use of prophylactic anticoagulants was
included in the guidelines, as well [13,14]. There are
opinions arguing that the protective effect demonstrated
in blood group O is based on this phenomenon [15]. The
present study, there was no significant relationship between
the clinical outcomes and the blood groups. However, this
is an important study amongst Turkish COVID-19 patients
that demonstrate the blood group A might be susceptible
to COVID-19 infection and the blood group O might be
somewhat protective which should be better elucidated in
prospective much larger studies, as well.
The limitation of this study is the somewhat small
number of patients with the clinical outcomes may have
caused the failure in demonstrating the effect of blood
groups on clinical outcomes in statistical terms.
In conclusion, the present study demonstrate that the
blood group O might be protective while the blood group
A might have increased susceptibility to the disease, and
guidelines set forth by the Centers for Disease Control and
Prevention (CDC), WHO and Healthy authorities, such as
social distancing, hand hygiene, mask use strictly should
be followed. One might conclude that stronger, stringent
measures should be taken when taking care of individuals
with the blood group A for possible COVID-19, i.e. SARSCoV-2 infection susceptibility. There is a need for further
molecular studies to elucidate the relationship between
the blood groups and the disease. Prospective larger
multicentre studies may be needed in order to further
elucidate the role of possible somewhat protective role of
the blood group O.
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